Racotumomab for treating lung cancer and pediatric refractory malignancies.

Abstract

INTRODUCTION:

Racotumomab (originally known as 1E10 mAb) is an anti-idiotype murine IgG1 directed to membrane glycoconjugates expressed in aggressive solid tumors. It was developed as a mirror image of the idiotype of another antibody against N-glycolyl-containing molecules, such as the NeuGcGM3 ganglioside. After a successful phase II/III study, racotumomab formulated in alum was conditionally approved in Latin American countries as maintenance therapy for advanced non-small cell lung cancer.

AREAS COVERED:

This review analyzes the biology of the target antigen, summarizes preclinical studies and discusses clinical trials in adults and the pediatric experience with racotumomab.

EXPERT OPINION:

Proper patient selection and combination with chemotherapy, radiotherapy or checkpoint inhibitors appear to be critical issues to maximize the effects of racotumomab vaccination in lung cancer. In a recent phase I clinical trial in children with relapsed or resistant neuroectodermal malignancies, racotumomab was well tolerated and immunogenic, and its evaluation as immunotherapy for high-risk neuroblastoma is warranted.

• Authors: Mariano R Gabri, Walter Cacciavillano, Guillermo L Chantada, Daniel F Alonso
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 16 Issue 4 Pg. 573-8 ( 2016) ISSN: 1744-7682 [Electronic] England
• PMID: 26903265 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Anti-Idiotypic
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Cancer Vaccines
• G(M3) Ganglioside
• racotumomab
• N-glycolylneuraminyllactosylceramide

Topics

• Animals
• Antibodies, Anti-Idiotypic (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Cancer Vaccines (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Child
• G(M3) Ganglioside (analogs & derivatives, immunology)
• Humans
• Lung Neoplasms (drug therapy)